Newsroom | 22985 results

Sorted by: Latest
Infectious Diseases
-

Imaginostics Receives Siemens Healthineers Letter of Support as Companies Advance Quantitative MRI Dialogue

ORLANDO, Fla.--(BUSINESS WIRE)--Imaginostics, Inc. today announced that it has received a Letter of Support from Siemens Healthineers in connection with ongoing exploratory discussions regarding potential collaboration in quantitative MRI and imaging biomarkers. As part of these discussions, Imaginostics and Siemens Healthineers intend to continue dialogue concerning potential technical and commercial pathways for Imaginostics’ envisioned ImagiView™ and ImagiSight™ offerings and their potential...
-

LEO Pharma to Present 17 Scientific Abstracts at AAD 2026 Highlighting Real‑World Evidence, Long‑Term Outcomes and Patient Experience Across Multiple Dermatological Conditions

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma to Present 17 Scientific Abstracts at AAD 2026...
-

Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray

CRYSTAL LAKE, Ill,--(BUSINESS WIRE)--Aptar’s Unidose Powder Nasal Delivery System Used in ENA Respiratory Phase II Clinical Study of Investigational INNA‑051 Nasal Spray...
-

QIAGEN Highlights Newly Published Data Supporting Efficacy of QuantiFERON for TB Prevention

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced newly published clinical and health economic data supporting the use of its QuantiFERON-TB Gold Plus (QFT-Plus) blood test for detecting tuberculosis (TB) infection, particularly in immunocompromised and other high-risk populations. The announcement is being made in time for World TB Day to underscore the continued importance of improving TB detection and prevention glo...
-

QIAGEN stellt neue Daten zur Wirksamkeit von QuantiFERON in der Tuberkulose-Prävention vor

GERMANTOWN, MD. & VENLO, NIEDERLANDE--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) hat heute die Veröffentlichung neuer klinischer und gesundheitsökonomischer Daten bekannt gegeben, die den Einsatz seines QuantiFERON-TB Gold Plus-Bluttests (QFT-Plus) zum Nachweis von Tuberkulose (TB)-Infektionen unterstützen, insbesondere bei immungeschwächten Personen und anderen Hochrisikogruppen. Die Bekanntgabe erfolgt im Vorfeld des Welttuberkulosetags und unterstreicht die anha...
-

Pattern Bioscience Surpasses 1,000 Samples in Multi-Center Clinical Trial of Rapid Pneumonia Diagnostic

AUSTIN, Texas--(BUSINESS WIRE)--More than 1,000 samples have been enrolled in the Pattern Bioscience clinical trial evaluating the Pattern Pneumonia ID/AST Panel and Pattern System...
-

Spring Has Sprung and So Have the Pests

FAIRFAX, Va.--(BUSINESS WIRE)--Ahead of spring, the National Pest Management Association (NPMA) warns that ants, termites, mosquitoes and ticks are already on the move....
-

iECURE Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of ECUR-506 Ahead of Planned BLA Submission

PHILADELPHIA--(BUSINESS WIRE)--iECURE, Inc., a clinical-stage genome editing company developing variant-agnostic in vivo targeted gene insertion therapies for the treatment of severe, inherited, neurometabolic disorders, today announced that the U.S. Food and Drug Administration (FDA) has selected ECUR-506, the company’s investigational in vivo targeted gene insertion therapy for neonatal-onset ornithine transcarbamylase (OTC) deficiency, to participate in the Chemistry, Manufacturing, and Cont...
-

ProImmune and the Roslin Institute Collaborate to Advance Animal Health Science

OXFORD, England & EDINBURGH, Scotland--(BUSINESS WIRE)--ProImmune Ltd, a global leader in immunological reagents and services, today announced a collaboration with the University of Edinburgh’s Roslin Institute to advance veterinary immunology research through development and validation of novel species-specific Ankyron® binders. Increased understanding of animal health through the application of ProImmune’s proprietary Ankyron binding technology will enable development of new strategies for pr...
-

AN2 Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business and Scientific Highlights

MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry platform, today reported financial results for the fourth quarter and year ended December 31, 2025. “Our recent decision to advance oral epetraborole into a Phase 2 study for polycythemia vera highlights the growing opportunity across AN2’s boron chemistry pipeline and...